Carl Schmid discusses the implications of the USPSTF Grade A rating of HIV PrEP to patients, providers, and payers.
Examines how insurance benefit design, including high deductibles and co-insurance, impact prescription drug access, along with the importance of copay assistance and how states are ensuring that it count towards beneficiary cost-sharing obligations.
Examines the federal requirement for private insurers to cover PrEP without cost-sharing, state actions to comply, transparency issues, and next steps for enforcing the requirement.
Discusses new requirement for private insurers to cover PrEP without cost-sharing, an early analysis of insurer compliance, and the need for federal and state enforcement.